SNSS - Sunesis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue6692,5363,0615,734
Cost of Revenue----
Gross Profit6692,5363,0615,734
Operating Expenses
Research Development21,54022,88123,70127,665
Selling General and Administrative13,54816,11518,66223,112
Non Recurring----
Total Operating Expenses35,08838,99642,36350,777
Operating Income or Loss-34,419-36,460-39,302-45,043
Income from Continuing Operations
Total Other Income/Expenses Net-1,039-1,5632,6262,041
Earnings Before Interest and Taxes-34,419-36,460-39,302-45,043
Interest Expense-1,396-1,721-939-1,719
Income Before Tax-35,458-38,023-36,676-43,002
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-35,458-38,023-36,676-43,002
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-35,458-38,023-36,676-43,002
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-35,458-38,023-36,676-43,002